Tesla could be a $10,000 stock in a decade, says longtime bull Ron Baron
Investing.com -- DBV Technologies (NASDAQ:DBVT) stock surged 7.2% in premarket trading Wednesday after the clinical-stage biopharmaceutical company announced it has completed the last patient visit in its Phase 3 VITESSE clinical trial of the VIASKIN Peanut patch.
The trial is evaluating the efficacy and safety of the VIASKIN Peanut patch in peanut-allergic children aged 4-7 years. With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.
"Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut allergic children, their physicians and caregivers, if approved," stated Daniel Tassé, Chief Executive Officer of DBV Technologies .
The VITESSE Phase 3 trial involves 654 subjects randomized in a 2:1 ratio across 86 sites in the U.S., Canada, Europe, the UK, and Australia. According to the company, it is currently the largest treatment intervention study in peanut allergy.
DBV Technologies is developing the VIASKIN Peanut patch as a potential treatment option for children with peanut allergies, a condition that affects millions worldwide and can cause severe allergic reactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.